Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period

6 novembre 2026 aggiornato da: Novartis Pharmaceuticals

VEX-AR: Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase 2 Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome, Followed by an Open-Label Extension Period

The purpose of this study is to evaluate clinical efficacy and safety of arumakimig (MAS825) compared to placebo in patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) syndrome. In addition, the study will evaluate the long-term efficacy, safety and tolerability of arumakimig in this population.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Descrizione dettagliata

This is a randomized, double-blind, placebo-controlled study with a 52-week duration evaluating the efficacy and safety of arumakimig in participants with VEXAS who are receiving glucocorticoids. Participants will be randomized 1:1 to either arumakimig or placebo.

Following the double-blind period, participants may have the option to enter a 2-year (104-week) open-label extension (OLE) period, continuing until Week 156.

A 16-week safety follow-up period must be completed after the OLE (up to Week 172) or after the double-blind period (up to Week 68).

Tipo di studio

Interventistico

Iscrizione (Stimato)

120

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

  • Nome: Novartis Pharmaceuticals
  • Numero di telefono: +41613241111

Luoghi di studio

      • Fukushima, Giappone, 9601295
        • Reclutamento
        • Novartis Investigative Site
      • Niigata, Giappone, 9518520
        • Reclutamento
        • Novartis Investigative Site
    • Kanagawa
      • Yokohama, Kanagawa, Giappone, 2360004
        • Reclutamento
        • Novartis Investigative Site
    • Osaka
      • Suita, Osaka, Giappone, 5650871
        • Reclutamento
        • Novartis Investigative Site
    • Tokyo
      • Hachiōji, Tokyo, Giappone, 1930998
        • Reclutamento
        • Novartis Investigative Site
      • Shinjuku-ku, Tokyo, Giappone, 1608582
        • Reclutamento
        • Novartis Investigative Site

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Male and female participants aged ≥18 years at screening.
  • Somatic mutation in UBA1 gene known to be associated with VEXAS.
  • Participants must have at least two manifestations of VEXAS at screening or in the past 6 months.
  • Participants must be able to start treatment for Pneumocystis jiroveci pneumonia (PJP) during the study if indicated according to the local guidelines.
  • Ability to communicate well with the Investigator, understand and agree to comply with the requirements of the study.

Exclusion Criteria:

  • Participants meeting any of the following criteria are not eligible for this study:
  • Positive serology for hepatitis B surface antigen (HBsAg) excludes the participant.

HBsAg negative participants who are hepatitis B core antibody (HBcAb) positive are also excluded unless protocol-defined criteria are met.

  • Participants with a positive HCV antibody test should have HCV ribonucleic acid (RNA) levels measured. Participants with positive (detectable) HCV RNA must be excluded. Chronic hepatitis C patients who have completed HCV anti-viral treatment must be HCV-RNA negative at least 12 weeks after treatment before randomization to be eligible.
  • Active viral, bacterial, or other infections requiring systemic treatment at the time of screening or randomization, or history of recurrent clinically significant infection or of recurrent bacterial infections.
  • Known or suspected Human Immunodeficiency Virus (HIV) infection. Should it be required by local regulations and/or considered appropriate by the Investigator, an HIV test can be performed locally to confirm eligibility.
  • Live vaccinations within a certain period prior to arumakimig treatment. Live vaccines are prohibited during the trial and up to a certain period following the last dose of arumakimig.
  • History of malignancy of any organ system, including post-transplant lymphoproliferative disorder (except for skin Bowen's disease, completely treated and resolved, localized squamous or basal cell carcinoma of the skin or actinic keratosis that have been treated with no evidence of recurrence in the past 12 weeks, in situ cervical cancer or non-invasive malignant colon polyps that have been removed), treated or untreated, within a protocol-defined period, regardless of whether there is evidence of local recurrence or metastases.
  • History of or current hepatic disease (moderate to severe Hepatic Impairment as per Child-Pugh classification), including but not limited to, acute or chronic hepatitis (for Hepatitis B or C), cirrhosis or hepatic failure.
  • Participants of child-bearing potential who do not agree to comply with required contraceptive use as outlined in the protocol.

Other protocol-defined inclusion/exclusion criteria may apply.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Arumakimig

Arumakimig from Day 1 to Week 52 during the double-blind period. Eligible participants may then continue into an open-label extension and receive arumakimig through Week 156.

Arumakimig Injection

Altri nomi:
  • MAS825

Background therapy with glucocorticoids. After the first 2 weeks of the study, participants may begin with glucocorticoid tapering depending on the disease status and the Investigator's judgement.

Comparatore placebo: Placebo

Placebo from Day 1 to Week 52 during the double-blind period. Eligible participants may then continue into an open-label extension and receive arumakimig through Week 156.

Arumakimig Injection

Altri nomi:
  • MAS825

Background therapy with glucocorticoids. After the first 2 weeks of the study, participants may begin with glucocorticoid tapering depending on the disease status and the Investigator's judgement.

Placebo Injection

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of participants achieving improvement of key VEXAS manifestations and oral glucocorticoid (GC) reduction at Week 52
Lasso di tempo: From baseline up to Week 52

Response is defined as meeting both criteria:

A) Clinical domain: In participants with clinical disease activity in any domain at baseline, complete resolution of clinical manifestations related to active disease in at least one affected domain. In participants with no clinical disease activity in any domain at baseline, continued absence of clinical manifestations in all domains at Week 52.

AND B) Protocol-defined glucocorticoid reduction through 52 weeks.

From baseline up to Week 52

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of participants achieving Overall Clinical Response (OCR) at Week 52
Lasso di tempo: From baseline up to Week 52

Achieving OCR at Week 52 is defined as meeting all the following criteria:

  • Absence of active inflammatory manifestations of VEXAS
  • Protocol-defined reduction in oral glucocorticoid.
  • Protocol-defined reduction in C reactive protein.
From baseline up to Week 52
Number of participants achieving resolution of VEXAS manifestations
Lasso di tempo: From baseline up to Week 52

In participants with clinical disease activity in any domain at baseline, achieving complete resolution of clinical manifestations.

From baseline up to Week 52
Number of participants with oral glucocorticoid reduction
Lasso di tempo: From baseline up to Week 52

Number of participants achieving protocol-defined glucocorticoid dose reduction through 52 weeks.

From baseline up to Week 52
Total number of flare-free days over 52 weeks
Lasso di tempo: Up to 52 weeks

Total cumulative number of days over 52 weeks meeting the protocol-defined criteria for a flare-free day.

Up to 52 weeks
Number of participants achieving Hematologic Improvement - Erythroid (HI-E) during the double-blind treatment period
Lasso di tempo: From baseline up to Week 52

Hematologic Improvement - Erythroid (HI-E) during the double-blind 52-week treatment period among participants with baseline hemoglobin within the protocol-defined range, according to modified International Working Group (IWG) and protocol-defined response criteria.

From baseline up to Week 52
Number of participants achieving Hematologic Improvement - Platelets (HI-P) during the double-blind treatment period
Lasso di tempo: From baseline up to Week 52

Hematologic Improvement - Platelets (HI-P) during the double-blind 52-week treatment period among participants with baseline platelets within the protocol-defined range, according to modified International Working Group (IWG) and protocol-defined response criteria.

From baseline up to Week 52
Number of participants without worsening disease according to a participant-reported questionnaire
Lasso di tempo: From baseline up to Week 52

Participants without protocol-defined worsening of disease according to a participant-reported questionnaire.

From baseline up to Week 52
Time to death during the double-blind treatment period
Lasso di tempo: Up to 52 weeks

Assessment of mortality through Week 52 in each treatment arm.

Up to 52 weeks
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Lasso di tempo: Up to 172 weeks

Number of participants with AEs and SAEs, including changes in vital signs, electrocardiograms and laboratory values qualifying and reported as AEs.

Up to 172 weeks

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

30 ottobre 2026

Completamento primario (Stimato)

26 dicembre 2028

Completamento dello studio (Stimato)

15 aprile 2031

Date di iscrizione allo studio

Primo inviato

31 luglio 2026

Primo inviato che soddisfa i criteri di controllo qualità

31 luglio 2026

Primo Inserito (Effettivo)

6 agosto 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

9 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

6 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi